Investigating how mitochondrial vesicles affect heart inflammation caused by a virus and differences between sexes
Official title: Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex
Funded at Mayo Clinic Jacksonville · NIH-10874609 · Data updated 2026-11-12
This study is looking at how tiny particles from cells might affect heart damage in myocarditis, especially in men, to help find new ways to treat this heart condition that can be caused by viruses like coxsackievirus B3.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $710,444 |
| NIH project number | 5R01HL164520-03 |
| Project ID | NIH-10874609 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with myocarditis, particularly those with a history of viral infections.
✕Less likely to help
Patients with myocarditis caused by non-viral factors or those who do not have a significant mitochondrial component to their condition may not benefit from this research.
What this research studies
This research focuses on understanding the role of mitochondrial extracellular vesicles in myocarditis, a serious heart condition often triggered by viral infections like coxsackievirus B3 (CVB3). The study aims to explore how these vesicles contribute to heart damage and why men are more severely affected than women. By examining the mechanisms of viral replication and the immune response in heart tissue, the research seeks to uncover potential therapeutic targets for myocarditis. Patients with myocarditis may benefit from insights gained into the disease's progression and potential new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for myocarditis, potentially reducing the risk of heart failure and the need for heart transplants.
How similar studies have gone: Previous research has shown that understanding the role of mitochondria in viral infections can lead to significant advancements in treatment, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Fairweather, Delisa — Mayo Clinic Jacksonville
- Study coordinator: Fairweather, Delisa
Related research
Other NIH-funded projects on the same topics.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Viral tricks that disrupt heart cell connections in myocarditis
This grant looks at how a common cold virus (adenovirus) may mess with the heart’s electrical signals and could lead to dangerous arrhythmias in people with myocarditis.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.